# Phase 10B Cross-Layer Evidence Synthesis and Candidate Scoring

## 1. Overview
This phase evaluates the candidates from the Phase 10A inventory against the locked multi-modal prioritization framework.

## 2. Evidence Synthesis
The candidates that achieved at least `PARTIALLY_REPLICATED` status in the cross-layer synthesis are:
- **HALLMARK_PROTEIN_SECRETION** (`MULTI_LAYER_SUPPORTED`)
- **BHLHE40** (`PARTIALLY_REPLICATED`)
- **CTCFL** (`PARTIALLY_REPLICATED`)
- **HALLMARK_SPERMATOGENESIS** (`PARTIALLY_REPLICATED`)

## 3. Target Prioritization

### HALLMARK_PROTEIN_SECRETION
While achieving the highest evidence tier (`MULTI_LAYER_SUPPORTED`), protein secretion is a broad, essential cellular process. It lacks a single tractable target and is likely pan-essential, making it a poor direct therapeutic candidate.

### BHLHE40
Classified as `PARTIALLY_REPLICATED`. Evaluation via OpenTargets and GTEx reveals it is a transcription factor with no high-quality binding pockets, no known inhibitors, and broad, high expression across normal tissues (e.g., Esophagus, Skin, Vagina). Therefore, BHLHE40 has low therapeutic viability due to high toxicity risk and low tractability.

### CTCFL (BORIS)
Classified as `PARTIALLY_REPLICATED`. GTEx analysis demonstrates classic Cancer-Testis Antigen (CTA) expression: median TPM is 7.6 in Testis, but <0.1 in all other 53 normal tissues. Although difficult to drug directly via small molecules as a transcription factor, its exquisite tumor-versus-normal selectivity makes it a compelling candidate for immunotherapy (e.g., TCR-T cells, cancer vaccines) with a very high safety ceiling.

## 4. Conclusion and Decision
- No traditional small-molecule targets successfully navigated the cross-layer computational pipeline and prioritization framework.
- **CTCFL** is highlighted as the most viable biological target to emerge from the host-microbiome synthesis, specifically for precision immunotherapeutic modalities.
- Status: `READY_FOR_MANUSCRIPT_DRAFTING`
